Quince Therapeutics’ stock crashes on Phase III ataxia-telangiectasia failure
Quince Therapeutics’ lead asset eDSP failed to meet the primary or secondary endpoints in the pivotal NEAT trial.
Therapy Area
Vitamin D deficiency increases the risk of respiratory tract infection
ImmunityBio’s glioblastoma regimen boosts survival in mid-stage study
Clearing the air: investigating the association between breast cancer and air pollution
Sanofi’s Dupixent successor heads to regulators after Phase III success
Corcept’s stock up as relacorilant meets OS goal in Phase III ovarian cancer trial
New data links eczema to inflammatory bowel and eye conditions
JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens
